Sectra, a leading international medical imaging IT and cybersecurity company, has made a significant move by acquiring Oxipit, a Lithuanian firm recognized for its advancements in artificial intelligence for radiology. This strategic acquisition, announced on March 5, 2026, highlights Sectra’s commitment to enhancing its autonomous AI capabilities in diagnostic imaging.
The Shift Towards Autonomous AI
Traditionally, AI tools in radiology serve as decision-support systems. They assist radiologists by flagging abnormalities, suggesting measurements, and helping prioritize cases. However, autonomous AI takes this a step further. It is designed to perform specific diagnostic tasks independently within defined clinical parameters, having undergone rigorous validation and regulatory approval. This represents a paradigm shift that promises to redefine the roles of radiologists and improve workflow efficiency.
Oxipit’s Innovative Solution
At the forefront of Oxipit’s technology is ChestLink, an autonomous AI solution that analyzes chest X-ray examinations. With its CE Class IIb certification, ChestLink can automatically identify and clear high-confidence normal cases from a radiologist’s workload. This innovation allows radiologists to allocate their time and expertise toward more complex cases that require human intervention. By streamlining routine tasks, ChestLink addresses the growing pressures of increased imaging volumes and staff shortages in radiology departments.
Integration into Sectra’s Ecosystem
The integration of Oxipit’s technology into Sectra’s existing framework is designed to be seamless. ChestLink is already accessible through the Sectra Amplifier Marketplace, which supports a wide range of AI applications. This vendor-neutral platform enables healthcare providers to incorporate various AI solutions into their radiology workflows, enhancing flexibility and choice.
Enhancing Radiologist Efficiency
Torbjörn Kronander, President and CEO of Sectra, emphasized the transformative potential of autonomous AI in radiology. By reducing the routine workload and enhancing productivity, Sectra aims to create a financial advantage for healthcare providers. This acquisition not only positions Sectra as a leader in this space but also underscores its commitment to improving patient care through innovative technology.
Oxipit’s Legacy and Future
Founded in 2017, Oxipit has developed a robust portfolio of CE-marked AI solutions for various imaging modalities, including chest X-ray, CT, and musculoskeletal imaging. These solutions are currently deployed in multiple international markets and have garnered recognition for their efficacy and safety. As a dedicated AI development center within Sectra, Oxipit’s team will continue to innovate and expand the capabilities of Sectra’s imaging solutions.
Financial Considerations
The acquisition will be financed through Sectra’s own resources, comprising an upfront cash payment and contingent considerations dependent on regulatory and commercial achievements. While the specific financial terms remain undisclosed, Sectra anticipates that this acquisition will not significantly impact its sales or operating profit for the current fiscal year.
Looking Ahead
As Sectra prepares to integrate Oxipit’s technologies and expand its AI offerings globally, the company is poised for growth. The regulatory approvals necessary to bring these innovations to more markets will be a priority, allowing Sectra to capitalize on the increasing demand for advanced imaging solutions.
Key Takeaways
- Sectra’s acquisition of Oxipit enhances its autonomous AI capabilities in diagnostic imaging.
- ChestLink, Oxipit’s flagship product, autonomously clears normal chest X-rays, optimizing radiologist workflows.
-
The integration of Oxipit’s technology into Sectra’s Amplifier Marketplace promotes a vendor-neutral ecosystem for healthcare providers.
-
The acquisition aims to improve efficiency and productivity in radiology, addressing workforce challenges.
-
Financial terms of the deal remain undisclosed, but it is not expected to materially affect Sectra’s current financial performance.
As Sectra continues to push the boundaries of medical imaging through innovation, the acquisition of Oxipit marks a significant milestone in its journey. This collaboration sets the stage for advancements that will not only reshape radiology but also enhance patient outcomes, making healthcare more efficient and effective.
Read more → www.prnewswire.co.uk